Abstract
Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
Original language | English (US) |
---|---|
Pages (from-to) | 105-112 |
Number of pages | 8 |
Journal | Seminars in Immunology |
Volume | 22 |
Issue number | 3 |
DOIs | |
State | Published - Jun 2010 |
Keywords
- Cancer
- Immunosurveillance
- Immunotherapy
- Vaccine(s)
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology